- Report
- February 2024
- 250 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,239GBP
- Report
- August 2022
- 118 Pages
Global
From €4324EUR$4,500USD£3,718GBP
- Report
- June 2020
- 155 Pages
Global
From €3459EUR$3,600USD£2,974GBP
- Report
- June 2022
- 102 Pages
Global
From €1922EUR$2,000USD£1,652GBP
Neulasta is a drug used to treat immune disorders, such as neutropenia, a condition in which the body does not produce enough white blood cells. Neulasta is a type of biologic therapy, which is a type of drug that is made from living cells. It works by stimulating the production of white blood cells, which helps the body fight infection. Neulasta is typically used in combination with chemotherapy to reduce the risk of infection in cancer patients. It is also used to treat other immune disorders, such as rheumatoid arthritis and Crohn's disease.
Neulasta is a widely used drug in the immune disorders market, and is available in both injectable and subcutaneous forms. It is typically administered in a hospital or clinic setting, and is usually given once a month. The drug is typically well-tolerated, with few side effects.
Companies in the Neulasta market include Amgen, Pfizer, and Johnson & Johnson. Show Less Read more